Horizon Discovery
2033 Westport Center Dr
St. Louis
Missouri
63146
United States
Tel: (314) 400-6627
Website: http://www.horizondiscovery.com/
Email: info@horizondiscovery.com
124 articles about Horizon Discovery
-
BioSpace Global Roundup, July 11
7/11/2019
Companies from across Europe, Asia and around the globe share pipeline and business updates. -
Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02
7/8/2019
Horizon Discovery Group plc, announced that Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.
-
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
-
Horizon Discovery Group plc Notice of Full Year Results
3/20/2019
Full year results for the year ended 31 December 2018 will be announced on Monday 29 April 2019.
-
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup...
-
Horizon Discovery and Rutgers University Form Exclusive Partnership to Develop Next Generation Novel Gene Editing Technology
1/28/2019
Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applications
-
Horizon Discovery partners with Biocartis to provide reference standards for recently launched Idylla™ microsatellite instability assay
11/1/2018
First commercially available reference standard for microsatellite instability (MSI) testing
-
Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia
9/26/2018
Horizon Discovery Group plc, announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.
-
Horizon Discovery Edit-R crRNA Libraries Adopted by AstraZeneca as Part of its Functional Genomics Discovery Platform
9/14/2018
AstraZeneca joins Horizon’s Genomics Discovery Initiative
-
Horizon Discovery announces collaboration with major pharmaceutical company on single cell RNAseq-linked CRISPR screening
8/28/2018
Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation
-
Hiring Roundup of Biotech Leaders
5/13/2018
Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies. -
Horizon Discovery’s Bioproduction Cell Line Used as Part of a Successful Drug (IND) Filing
3/21/2018
Horizon’s Glutamine Synthetase-Knockout CHO K1 cell line has been used as part of a successful Investigational New Drug filing with the FDA
-
Horizon Discovery Enters into License Agreement With US Immuno-Oncology Company
2/12/2018
Under the terms of the agreement, Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.
-
Horizon Discovery Enters into License Agreement With U.S. Immuno-Oncology Company
2/12/2018
Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon's proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.
-
Horizon Discovery Group plc Pre-Close Period Update
2/1/2018
Horizon Discovery today announces an unaudited pre-close period update for the year ended 31 December 2017.
-
Horizon Discovery's Dharmacon Introduces Edit-R CRISPRa Reagent Platform for Genome-Wide CRISPR Activation
11/14/2017
This is the latest addition to the Company’s market-leading Edit-R portfolio for CRISPR-Cas9 genome engineering.
-
Horizon Discovery Partners With the Michael J. Fox Foundation to Introduce Novel Pre-Clinical Models for Parkinson's Disease
10/31/2017
Horizon Discovery introduced two new gene knock-out and knock-in rat models for investigating the role of alpha-synuclein in brain function and Parkinson's disease (PD) pathogenesis.
-
Horizon Discovery Introduces OncoSpan, The World’s Largest DNA Multiplex Reference Standard For Oncology
9/25/2017
-
Horizon Discovery Announces Launch Of Genome-Wide CRISPRi And CRISPRa Screening Services
9/19/2017
-
Horizon Discovery Announces Release Of High Quality, Well Annotated CHO Genome Sequence To Drive Innovation In Bioproduction
8/1/2017